Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study

Abstract

Background Patients with antipsychotic-naïve first-episode (ANFE) schizophrenia (SZ) can help clarify many confounding factors in determining sex differences in antipsychotic drug induced weight gain and its association with symptom improvement.

Methods This 8-week longitudinal trial of ANFE patients with SZ enrolled 526 patients and 313 healthy controls. We evaluated bodyweight and the efficacy of antipsychotics on the Positive and Negative Syndrome Scale (PANSS) at baseline and at the end of week 8.

Results Males and females after treatment showed no sex difference in weight gain, BMI increase, and percentage of weight gain. However, at baseline, male patients had more positive symptoms than female patients, and decreases in positive symptoms, general psychopathology, and total PANSS scores were less in male than female patients. Adjusting for confounding factors using multiple linear regression confirmed that weight gain was significantly associated with these decreases in PANSS symptoms only in men not women.

Conclusions The relationship between weight gain and symptom reduction after 8 weeks of antipsychotic treatment exists only in male patients with ANFE SZ and not in female patients.

Key words

schizophrenia, sex difference, weight gain - therapeutic response - body mass index

Publication History

Received: 12 August 2020
Received: 21 December 2020

Accepted: 11 January 2021

Article published online:
24 February 2021

• References

• 1 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
• 2 Mizuno Y, Suzuki T, Nakagawa A. et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40: 1385-1403
• 3 Pillinger T, McCutcheon RA, Vano L. et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64-77
• 4 Zhou Y, Li Y, Meng Y. et al. Neuregulin 3 rs10748842 polymorphism contributes to the effect of body mass index on cognitive impairment in patients with schizophrenia. Transl Psychiatry 2020; 10: 62
• 5 Cowell PE, Kostianovsky DJ, Gur RC. et al. Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry 1996; 153: 799-805
• 6 Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28: 17-54
• 7 Ochoa S, Usall J, Cobo J. et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012; 2012: 916198
• 8 Lang XE, Zhu D, Zhang G. et al. Sex difference in association of symptoms and white matter deficits in first-episode and drug-naive schizophrenia. Transl Psychiatry 2018; 8: 281
• 9 Wei CW, Chen YQ, Ma M. et al. Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia. Transl Psychiatry 2020; 10: 18
• 10 Guo X, Zhang Z, Wei Q. et al. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 2013; 13: 109
• 11 de Leon J, Diaz FJ, Josiassen RC. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007; 27: 6
• 12 Seeman MV. Does gender influence outcome in schizophrenia?. Psychiatr Q 2019; 90: 173-184
• 13 Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med 2003; 33: 1149-1160
• 14 Law MR, Soumerai SB, Ross-Degnan D. et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008; 69: 47-53
• 15 Lange B, Mueller JK, Leweke FM. et al. How gender affects the pharmacotherapeutic approach to treating psychosis—a systematic review. Expert Opin Pharmacother 2017; 18: 351-362
• 16 Robinson D, Woerner MG, Alvir JM. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247
• 17 Ceskova E, Prikryl R. Importance of gender in the treatment of schizophrenia. Prim Care Companion CNS Disord 2012; 14
• 18 Leadbetter R, Shutty M, Pavalonis D. et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72
• 19 Czobor P, Volavka J, Sheitman B. et al. Antipsychotic-induced weight gain and therapeutic response: A differential association. J Clin Psychopharmacol 2002; 22: 244-251
• 20 Ascher-Svanum H, Stensland MD, Kinon BJ. et al. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 2005; 19: 110-117
• 21 Bai YM, Lin CC, Chen JY. et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163: 1276-1279
• 22 Bellavia A, Centorrino F, Jackson JW. et al. The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: an analysis of the CATIE schizophrenia trial. Schizophr Res 2019; 206: 96-102
• 23 Allison DB, Fontaine KR, Heo M. et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215-220
• 24 Raben AT, Marshe VS, Chintoh A. et al. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front Neurosci 2017; 11: 741
• 25 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939-951
• 26 Bai YM, Lin CC, Chen JY. et al. Weight gain among patients on clozapine. Psychiatr Serv 1999; 50: 704-705
• 27 Hung GC, Kuo CJ, Huang MC. et al. Sex differences in the association of weight gain and risperidone efficacy among schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1523-1524
• 28 Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959; 20: 53-57
• 29 Holden JM, Holden UP. Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970; 11: 551-561
• 30 Konarzewska B, Waszkiewicz N, Galinska B. et al. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone. Neuro Endocrinol Lett 2013; 34: 322-328
• 31 Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003; 59: 19-27
• 32 Ascher-Svanum H, Stensland M, Zhao Z. et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005; 5: 3
• 33 Lieberman DL, Tybur JM, Latner JD. Disgust sensitivity, obesity stigma, and gender: contamination psychology predicts weight bias for women, not men. Obesity (Silver Spring) 2012; 20: 1803-1814
• 34 Lieberman JA, Phillips M, Gu H. et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003
• 35 Phillips MR, Zhang J, Shi Q. et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. Lancet 2009; 373: 2041-2053
• 36 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
• 37 Talonen S, Vaananen J, Kaltiala-Heino R. Gender differences in first onset Schizophrenia spectrum psychoses. Nord J Psychiatry 2017; 71: 131-138
• 38 Zhang XY, Chen DC, Xiu MH. et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry 2012; 73: 1025-1033
• 39 Chen S, Broqueres-You D, Yang G. et al. Male sex may be associated with higher metabolic risk in first-episode schizophrenia patients: A preliminary study. Asian J Psychiatr 2016; 21: 25-30
• 40 Goldstein JM, Seidman LJ, Goodman JM. et al. Are there sex differences in neuropsychological functions among patients with schizophrenia?. Am J Psychiatry 1998; 155: 1358-1364
• 41 Thorup A, Petersen L, Jeppesen P. et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis 2007; 195: 396-405
• 42 Ceskova E, Prikryl R, Libiger J. et al. Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial. Schizophr Res 2015; 169: 303-307
• 43 Szymanski S, Lieberman JA, Alvir JM. et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995; 152: 698-703
• 44 Cotton SM, Lambert M, Schimmelmann BG. et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009; 114: 17-24
• 45 Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010; 22: 417-428
• 46 Damoiseaux VA, Proost JH, Jiawan VC. et al. Sex differences in the pharmacokinetics of antidepressants: Influence of female sex hormones and oral contraceptives. Clin Pharmacokinet 2014; 53: 509-519
• 47 Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II. J Womens Health Gend Based Med 2002; 11: 617-629
• 48 Bigos KL, Bies RR, Pollock BG. et al. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 2011; 16: 620-625
• 49 Jukic MM, Smith RL, Haslemo T. et al. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: A retrospective, cohort study. Lancet Psychiatry 2019; 6: 418-426
• 50 Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and secondgeneration antipsychotics. Expert Opin Drug Metab Toxicol 2014; 10: 26
• 51 Seeman MV. Are there gender differences in the response to antipsychotic drugs?. Neuropharmacology 2019; 23: 8
• 52 Lane HY, Chang YC, Chang Wh. et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999; 60: 36-40
• 53 Gex-Fabry M, Balant-Gorgia AE, Balant LA. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53
• 54 Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 2016; 55: 1353-1368
• 55 Meltzer HY, Rabinowitz J, Lee MA. et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997; 154: 475-482
• 56 Li Q, Chen D, Liu T. et al. Sex differences in body mass index and obesity in chinese patients with chronic schizophrenia. J Clin Psychopharmacol 2016; 36: 643-648
• 57 Muller DJ, Klempan TA, De Luca V. et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81-89
• 58 Aichhorn W, Stelzig-Schoeler R, Geretsegger C. et al. Bright light therapy for negative symptoms in schizophrenia: a pilot study. J Clin Psychiatry 2007; 68: 1146
• 59 Haack S, Seeringer A, Thürmann PA. et al. Sex-specific differences in side effects of psychotropic drugs: Genes or gender?. Pharmacogenomics 2009; 10: 1511-1526
• 60 Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161: 1324-1333
• 61 Kaar SJ, Natesan S, McCutcheon R. et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2019; 107704
• 62 Seyfart T, Friedrich N, Kische H. et al. Association of sex hormones with physical, laboratory, and imaging markers of anthropometry in men and women from the general population. PLoS One 2018; 13: e0189042
• 63 Hennen J, Perlis RH, Sachs G. et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry 2004; 65: 1679-1687